730 results on '"Lacasce, A. S."'
Search Results
2. Frontline management of mantle cell lymphoma
3. A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma
4. A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma
5. Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States
6. Detection of Maternal Malignancy After Abnormal Noninvasive Prenatal Testing: A Single-Center Case Series
7. Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis
8. Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
9. Evaluation of mediastinal lymph node segmentation of heterogeneous CT data with full and weak supervision
10. A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
11. Putting the Heme Back in Heme-Onc: an Evaluation of the Redesigned Hematology Track within the Dana Farber/Mass General Brigham Hematology-Oncology Fellowship
12. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation
13. A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma
14. Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study
15. Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor–induced dermatologic adverse events
16. Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma
17. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
18. Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
19. Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL
20. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study
21. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
22. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma
23. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
24. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation
25. Clinical Evaluation and Management of Hodgkin Lymphoma
26. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma
27. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma
28. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial
29. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
30. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
31. Frontline Treatment of Mantle Cell Lymphoma
32. Case Report: Post-transplant lymphoproliferative disorder as a serious complication of vascularized composite allotransplantation
33. Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP
34. Non-Hodgkin's lymphomas, version 4.2014.
35. Posttransplant Lymphoproliferative Disorders
36. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
37. Positron emission tomography–computed tomography predictors of progression after DA-R-EPOCH for PMBCL
38. Long-Term Reduction in Peripheral Blood HIV Type 1 Reservoirs Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation
39. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
40. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma
41. Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy
42. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023
43. A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma
44. Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1
45. How to Approach a Patient With Limited Stage Hodgkin Lymphoma Who Remains PET Positive at the End of Chemotherapy: Radiation Therapy?
46. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction
47. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
48. Clinical Evaluation and Management of Hodgkin Lymphoma
49. The International Prognostic Index: still relevant 30 years later
50. Improved survival in cHL with novel agents
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.